SynBio companies successful in Innovate UK competition 'Developing Regenerative Medicines and Cell Therapies'
Five exciting projects have secured funding throught the Innovate UK funding competition 'Developing Regenarative Medicines and Cell Therapies', at least two of which take a synthetic biology approach.
Touchlight Genetics Ltd will work with project lead Cobra Biologics to develop a fast and less expensive route to manufacture Adeno-associated Viirus (AAV) vectors, the delivery vehicle of choice for gene therapy treatments. A further collaboraton between Cobra Biologics and CPI will also explore the scaleability of AAV vector production, and Synpormics Ltd will work with the Cell Therapy Catapult to create new methods of producing large quantities of virus at a low cost.
These projects will enable the acceleration of more potential products into clinical testing, which will, in turn, increase the chances of treatment being developed for a whole range of currently intractable diseases.
Read the full story in this Innovate UK blog.